^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HYAL4 V1

    i
    Other names: Hyaluronidase 4, Chondroitin Sulfate Endo-Beta-N-Acetylgalactosaminidase, Chondroitin Sulfate Hydrolase, Hyaluronoglucosaminidase 4, Hyaluronidase-4, CSHY, Hyaluronoglucosaminidase-4, HYAL-4 Variant 1, HYAL-4, Hyal-4, HYAL4
    Entrez ID:
    23553
    2years
    Alternative splicing in bladder cancer: potential strategies for cancer diagnosis, prognosis, and treatment. (PubMed, Wiley Interdiscip Rev RNA)
    This review represents the first detailed overview of the splicing process and its alterations in bladder cancer, and highlights opportunities for the development of novel diagnostic/prognostic biomarkers and their clinical potential for the treatment of this devastating cancer type. This article is categorized under: RNA Processing > Splicing Regulation/Alternative Splicing RNA in Disease and Development > RNA in Disease.
    Review • Journal • IO biomarker
    |
    HYAL4 (Hyaluronidase 4) • PTBP1 (Polypyrimidine Tract Binding Protein 1) • PKM (Pyruvate Kinase M1/2)
    |
    HYAL4 V1
    over3years
    [VIRTUAL] Newly Discovered Chondroitinase HYAL4-V1 drives Gemcitabine Resistance and Predicts Gemcitabine/Cisplatin Failure in Bladder Cancer Patients (AUA 2021)
    V1 drives Gemcitabine resistance and potentially predicts G+C failure. Combination with Tetrahydrouridine overcomes Gemcitabine resistance. Since Gemcitabine is included in several chemotherapy regimens, our study could have broad significance.
    Clinical
    |
    HYAL4 (Hyaluronidase 4)
    |
    HYAL4 V1
    |
    cisplatin • gemcitabine